Table 1.
Isolate selected | Adherence capabilities | Dru typing | Sequence type | Origin location |
---|---|---|---|---|
A3 |
LOW |
9a |
71 |
U.S.A |
A12 |
STRONG |
10h |
68 |
U.S.A |
A23 |
STRONG |
10a |
68 |
U.S.A |
A46 |
MODERATE |
9a |
71 |
U.S.A |
A56 |
LOW |
9a |
71 |
U.S.A |
A92 |
MODERATE |
9a |
71 |
U.S.A |
SP87 |
LOW |
9a |
71 |
Canada |
SP88 |
LOW |
9a |
71 |
Canada |
SP90 |
STRONG |
9a |
71 |
Canada |
SP91 |
LOW |
9a |
71 |
Canada |
SP93 |
LOW |
9a |
71 |
Canada |
SP102 |
LOW |
11a |
68 |
Canada |
SP104 |
MODERATE |
10h |
68 |
Canada |
SP105 |
MODERATE |
10h |
68 |
Canada |
SP106 |
MODERATE |
9a |
71 |
Canada |
SP112 |
MODERATE |
9a |
71 |
Canada |
SP113 |
MODERATE |
9a |
71 |
Canada |
SP114 |
LOW |
9a |
71 |
Canada |
SP115 |
LOW |
9a |
71 |
Canada |
SP116 | LOW | 9a | 71 | Canada |
Dru typing of chosen biofilm forming isolates of MRSP reveals a representative population of strains commonly found in veterinary hospitals across North America. Adherence capabilities were determined based on the model developed by Stepanovic et al., 2000.